Positives

• A published case report describes a 37-year-old rheumatoid arthritis patient with Long COVID whose brain fog and fatigue worsened during a 10-day Actemra hold and then resolved within three weeks of resuming the IL-6 blocker, with the headache also easing Frontiers.
• Drugs.com reviewers using Actemra for rheumatoid arthritis often mention fatigue improvement, with one writing “life has come back” after a year and a half and another saying joint pain, stiffness, and fatigue dropped from a 9 to a 6 between infusions Drugs.com.

Negatives

• Across 36 RA reviews on Drugs.com, 31% of Actemra users describe a negative experience, with one patient reporting that after two years on the drug their fatigue became so significant they could no longer work, and others citing recurrent infections and mouth sores Drugs.com.
• ME/CFS patients who tried Actemra for cytokine-driven symptoms report mixed results, with several saying they noticed no durable benefit despite the cost and infusion burden Phoenix Rising.

Hurdles & Side Effects

• Drugs.com lists Actemra IV at about $526 for a 4 mL vial and the subcutaneous pen at roughly $1,155 per 0.9 mL, and access for Long COVID is off-label so most patients need a sympathetic rheumatologist plus prior authorization to get it covered Drugs.com.
• Patient education from Johns Hopkins notes Actemra requires either monthly IV infusions or weekly self-injections, ongoing lab monitoring for liver enzymes and lipids, and that some patients wait 8+ weeks before they can tell whether it is helping Johns Hopkins.